Previous Close | 0.6111 |
Open | 0.6500 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 3100 |
Day's Range | 0.6151 - 0.6600 |
52 Week Range | 0.3300 - 10.4200 |
Volume | |
Avg. Volume | 315,941 |
Market Cap | 24.248M |
Beta (5Y Monthly) | 1.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.4260 |
Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.25 |
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq:
Potential Applied Molecular Transport Inc. ( NASDAQ:AMTI ) shareholders may wish to note that the Independent Director...